Arthur M. Cohen & Associates LLC Has $3.31 Million Stake in Johnson & Johnson (NYSE:JNJ)

Arthur M. Cohen & Associates LLC grew its position in Johnson & Johnson (NYSE:JNJ) by 0.6% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 23,514 shares of the company’s stock after purchasing an additional 150 shares during the quarter. Johnson & Johnson makes up about 1.0% of Arthur M. Cohen & Associates LLC’s portfolio, making the stock its 19th largest position. Arthur M. Cohen & Associates LLC’s holdings in Johnson & Johnson were worth $3,307,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Capital World Investors boosted its holdings in shares of Johnson & Johnson by 182.9% during the 1st quarter. Capital World Investors now owns 21,195,989 shares of the company’s stock worth $2,779,435,000 after buying an additional 13,703,905 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Johnson & Johnson by 10.8% in the 1st quarter. Wellington Management Group LLP now owns 30,556,662 shares of the company’s stock valued at $4,006,895,000 after acquiring an additional 2,968,879 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its position in shares of Johnson & Johnson by 7.7% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 29,526,058 shares of the company’s stock valued at $3,871,753,000 after acquiring an additional 2,118,870 shares during the period. Capital International Investors boosted its stake in Johnson & Johnson by 13.6% during the first quarter. Capital International Investors now owns 16,726,965 shares of the company’s stock worth $2,193,411,000 after acquiring an additional 2,004,688 shares in the last quarter. Finally, Swiss National Bank grew its holdings in Johnson & Johnson by 21.9% in the first quarter. Swiss National Bank now owns 11,147,766 shares of the company’s stock worth $1,461,807,000 after purchasing an additional 2,003,900 shares during the period. Institutional investors own 68.44% of the company’s stock.

A number of equities analysts have recently issued reports on the stock. Wells Fargo & Co raised shares of Johnson & Johnson to a “hold” rating in a research report on Wednesday, April 22nd. Bank of America reissued a “buy” rating on shares of Johnson & Johnson in a research note on Monday, July 20th. ValuEngine lowered Johnson & Johnson from a “hold” rating to a “sell” rating in a research report on Wednesday, July 15th. Independent Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and increased their target price for the stock from $161.00 to $164.00 in a report on Monday, July 20th. Finally, Citigroup boosted their price target on shares of Johnson & Johnson from $165.00 to $170.00 and gave the company a “buy” rating in a research note on Friday, July 17th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and twelve have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $163.38.

In related news, EVP Ashley Mcevoy sold 29,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $147.47, for a total value of $4,276,630.00. Following the transaction, the executive vice president now owns 21,682 shares in the company, valued at $3,197,444.54. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.27% of the company’s stock.

Johnson & Johnson stock opened at $145.76 on Friday. Johnson & Johnson has a 52 week low of $109.16 and a 52 week high of $157.00. The company’s 50 day moving average price is $144.04 and its two-hundred day moving average price is $144.14. The stock has a market cap of $383.76 billion, a P/E ratio of 21.31, a P/E/G ratio of 3.23 and a beta of 0.69. The company has a quick ratio of 1.05, a current ratio of 1.25 and a debt-to-equity ratio of 0.40.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Thursday, July 16th. The company reported $1.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.50 by $0.17. Johnson & Johnson had a return on equity of 35.21% and a net margin of 22.69%. The firm had revenue of $18.34 billion during the quarter, compared to analyst estimates of $17.73 billion. During the same period last year, the firm posted $2.58 EPS. The business’s revenue was down 10.8% compared to the same quarter last year. On average, equities analysts anticipate that Johnson & Johnson will post 7.85 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be paid a dividend of $1.01 per share. The ex-dividend date is Monday, August 24th. This represents a $4.04 annualized dividend and a dividend yield of 2.77%. Johnson & Johnson’s payout ratio is currently 46.54%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

See Also: Using other technical indicators with support levels

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.